Elicio Therapeutics, Inc.

ELTX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$10,083-$10,561-$11,209-$14,004
Dep. & Amort.$283$281$278$305
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$710$517$464
Change in WC-$4,179-$351-$354$3,685
Other Non-Cash$2,893$971$649$806
Operating Cash Flow-$11,086-$8,950-$10,119-$8,744
Investing Activities
PP&E Inv.$0$0$0-$45
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0-$45
Financing Activities
Debt Repay.$9,866$0$0$0
Stock Issued-$294$2,016$10,328$222
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$9,916$0$5
Financing Cash Flow$9,572$11,932$10,328$227
Forex Effect$37$74$31$27
Net Chg. in Cash-$1,477$3,056$240-$8,535
Supplemental Information
Beg. Cash$22,088$19,732$19,492$28,027
End Cash$20,611$22,788$19,732$19,492
Free Cash Flow-$11,086-$8,950-$10,119-$8,789
Elicio Therapeutics, Inc. (ELTX) Financial Statements & Key Stats | AlphaPilot